<DOC>
	<DOCNO>NCT00805090</DOCNO>
	<brief_summary>An open-label , single-dose study evaluate safety pharmacokinetics DIC075V subject mild moderate chronic renal insufficiency patient mild chronic hepatic impairment compare . Additionally , healthy adult volunteer participate randomize , open-label , crossover study receive Sporanox® compare safety pharmacokinetics HPβCD administer DIC075V compare Sporanox® .</brief_summary>
	<brief_title>Open-Label , Single-Dose Study Evaluate Safety PK DIC075V Subjects With Renal Insufficiency Hepatic Impairment Compared Healthy Subjects Evaluate Safety Pharmacokinetics HPβCD When Administered DIC075V Compared Sporanox® Healthy Subjects</brief_title>
	<detailed_description>For renal hepatic subject , follow screen visit , eligible subject return study site Study Day 0 remain site 2 night 2 day . Study drug administration occur Study Day 1 . Subjects discharge Study Day 2 last blood sample collect . Subjects return 7 ± 3 day dose study drug final safety assessment perform . For healthy subject , follow screen visit , eligible subject return study site Study Day 0 remain site 3 night 3 day . Study drug administration occur Study Day 1 Study Day 2 . Subjects discharge Study Day 3 last blood sample collect . Subjects return 7 ± 3 day receive last dose study drug final safety assessment perform .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Inclusion Criteria ( General ) : The subject must males female ≥ 18 year age ≤ 65 year . The subject must willing able provide sign informed consent . The subject must willing able stay clinical site require number day night return clinic 7 ± 3 day dose study drug . Inclusion Criteria ( subject mild moderate chronic renal insufficiency ) : The subject must mild moderate chronic renal insufficiency document history stable renal disease 1 month prior screen clinical laboratory test result consistent underlying disease renal impairment . Inclusion Criteria ( subject mild chronic hepatic impairment ) : The subject must mild chronic hepatic impairment , define ChildPugh Classification A , Score 56 bilirubin ≤ 2.5 mg/dl . Inclusion Criteria ( healthy subject ) : Healthy subject match renally impaired subject study age ( + 10 year ) , gender , body weight ( ± 10 kg ) . The subject know allergy hypersensitivity diclofenac , NSAIDs , excipients study preparation ( hydroxypropylßcyclodextrin ( HPßCD ) , monothioglycerol , sodium hydroxide , hydrochloric acid , water injection ) , itraconzaole `` azole '' drug , excipients Sporanox ( HPßCD , propylene glycol , sodium hydroxide , hydrochloric acid , water injection ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Renal</keyword>
	<keyword>Hepatic</keyword>
	<keyword>Healthy</keyword>
</DOC>